Fast Market Research

N30 Pharmaceuticals - Product Pipeline Review - 2012 - New Market Report Now Available

New Pharmaceuticals market report from Global Markets Direct: "N30 Pharmaceuticals - Product Pipeline Review - 2012"


Boston, MA -- (SBWIRE) -- 02/07/2013 -- Global Market Direct's pharmaceuticals report, "N30 Pharmaceuticals - Product Pipeline Review - 2012" provides data on the N30 Pharmaceuticals's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, N30 Pharmaceuticals's corporate website, SEC filings, investor presentations and featured press releases, both from N30 Pharmaceuticals and industry-specific third party sources, put together by Global Markets Direct's team.


- N30 Pharmaceuticals - Brief N30 Pharmaceuticals overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of N30 Pharmaceuticals human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of N30 Pharmaceuticals with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the N30 Pharmaceuticals's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Evaluate N30 Pharmaceuticals's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of N30 Pharmaceuticals in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the N30 Pharmaceuticals's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with N30 Pharmaceuticals.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of N30 Pharmaceuticals and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Inflammatory Bowel Disease - Pipeline Review, H1 2012
- Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2012
- Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2012
- Merrimack Pharmaceuticals, Inc. - Product Pipeline Review - 2012
- Spectrum Pharmaceuticals, Inc. - Product Pipeline Review - 2012
- Threshold Pharmaceuticals, Inc. - Product Pipeline Review - 2012
- Astex Pharmaceuticals, Inc. - Product Pipeline Review - 2012
- Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2012
- Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2012
- Hanmi Pharmaceuticals, Co. Ltd. - Product Pipeline Review - 2012